Back to top
more

Alvotech (ALVO)

(Delayed Data from NSDQ)

$13.02 USD

13.02
79,145

+0.04 (0.31%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $12.99 -0.03 (-0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are Medical Stocks Lagging Alvotech (ALVO) This Year?

by Zacks Equity Research

Here is how Alvotech (ALVO) and Atossa Genetics Inc. (ATOS) have performed compared to their sector so far this year.

Here's Why You Should Consider Buying Alvotech (ALVO) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Alvotech (ALVO) stock now may turn out to be a prudent move.

TEVA Stock Rises 135% in a Year: What's Driving the Recovery?

by Zacks Equity Research

TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.

Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar

by Zacks Equity Research

Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 20% and 6.17%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of 5% and 51.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of 11.41% and 5.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Alvotech (ALVO) Up on BLA Update for Two Biosimilar Candidates

by Zacks Equity Research

The FDA concludes the reinspection of Alvotech's (ALVO) facility in Iceland. The company believes that it may receive approval for biosimilar candidates, AVT02 and AVT04, in the United States. Stock rises.

Alvotech (ALVO)'s Technical Outlook is Bright After Key Golden Cross

by Zacks Equity Research

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate

by Zacks Equity Research

Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.

Wall Street Analysts Think Alvotech (ALVO) Could Surge 119%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Alvotech (ALVO) points to an 119.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Bears are Losing Control Over Alvotech (ALVO), Here's Why It's a 'Buy' Now

by Zacks Equity Research

Alvotech (ALVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.